Nurix Therapeutics (NRIX) Presents At American Society of Hematology Meeting - Slideshow

NX-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies Presenter: Daniel Robbins, Ph. D. drobbins@nurixtx.com Disclosures All authors of this presentation are current or former employees and shareholders of Nurix Therapeutics. 2 ©Nurix Therapeutics. All rights reserved. NX-2127 has a dual degradation mechanism of action for two clinically validated targets • BTK is a tyrosine kinase involved in B cell development, differentiation and signaling • BTK inhibitors are approv ...